Raymon Heather
Known title: SVP, Research and DevelopmentCIK: 0002028466
Associated companies
Transaction History
| ARTV | ▼ Sell | Open Market | 3,095 | $28K | 5/19/2026 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 1,521 | $6K | 2/15/2026 | View on chart |
| ARTV | ▲ Buy | Grant | 46,000 | $0 | 2/15/2026 | View on chart |
| ARTV | ▲ Buy | Grant | 67,253 | $0 | 12/12/2025 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 1,375 | $4K | 11/15/2025 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 1,639 | $5K | 8/15/2025 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 745 | $2K | 5/15/2025 | View on chart |
| ARTV | ▲ Buy | Grant | 33,350 | $0 | 2/26/2025 | View on chart |
| ARTV | ▲ Buy | Grant | 10,000 | $0 | 9/12/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
ARTV Announces Oral Presentation of AlloNK Data at Sjögren’s Symposium
Artiva Biotherapeutics will give an oral presentation of its AlloNK® clinical data at the 17th International Symposium on Sjögren’s Disease. The talk focuses on early results from a study in patients with this autoimmune disorder. The data could influence how investors view the company’s therapeutic pipeline. The presentation is a milestone before any formal publication or regulatory filing.
ARTV Announces Oral Presentation of AlloNK Data at Sjögren’s Symposium. Artiva Biotherapeutics will give an oral presentation of its AlloNK® clinical data at the 17th International Symposium on Sjögren’s Disease. The talk focuses on early results from a study in patients with this autoimmune disorder. The data could influence how investors view the company’s therapeutic pipeline. The presentation is a milestone before any formal publication or regulatory filing.